Literature DB >> 28053818

Association between Serum Magnesium Levels and Depression in Stroke Patients.

Yingying Gu1, Kai Zhao1, Xiaoqian Luan1, Zhihua Liu1, Yan Cai1, Qiongzhang Wang1, Beilei Zhu1, Jincai He1.   

Abstract

Post-stroke depression (PSD) is a common psychiatric complication of stroke that is associated with a poor outcome in stroke patients. Our aim was to assess the association between the serum magnesium levels and the presence of PSD in Chinese patients. Two hundred nine stroke patients were included in the study. Depressive symptoms were measured by the 17-Hamilton Rating Scale for Depression at 3 months after stroke. Based on the depressive symptoms, diagnoses of depression were made in line with the DSM-IV criteria for PSD. Serum magnesium levels were evaluated using the dimethyl aniline blue colorimetric method at admission. Multivariate analyses were conducted using logistic regression models. Further, 120 normal subjects were recruited, and their serum magnesium levels were also measured as control. At 3 months, fifty-nine patients (28.2%) were diagnosed as PSD. The serum magnesium levels were significantly lower in both PSD patients and non-PSD patients than in normal subjects (p < 0.001). Indeed, patients with PSD showed lower serum magnesium levels (p < 0.001) than did non-PSD patients at admission. In the multivariate analyses, after adjusting for potential variables, we found that an increased risk of PSD was associated with serum magnesium levels ≤ 0.84mmol/L (OR 2.614, 95% CI 1.178-5.798, p=0.018). Low serum magnesium levels at admission were found to be associated with the presence of PSD at 3 months after stroke.

Entities:  

Keywords:  biochemical marker; depression; magnesium; stroke

Year:  2016        PMID: 28053818      PMCID: PMC5198859          DOI: 10.14336/AD.2016.0402

Source DB:  PubMed          Journal:  Aging Dis        ISSN: 2152-5250            Impact factor:   6.745


Depression is the most common psychiatric complication encountered by stroke survivors, and affects approximately one third of stroke patients at any time during the follow up [1]. Post-stroke depression (PSD) has a negative impact on outcomes in the forms of greater functional disability, lower quality of life and higher mortality [2, 3]. Magnesium (Mg2+) plays a significant role in the physiological function of the brain. Low levels of serum Mg2+ have been suggested to play a role in the biological dysregulation contributing to depression. Experimentally induced Mg2+ deficiency resulted in depression-like behavior in mice [4], and a recently study suggested that an antidepressant-like activity of Mg2+ in an animal model of anhedonia for the first time [5]. In addition, a growing body of evidence indicated an inverse relationship between Mg2+ intake and the risk of stroke [6-9]. However, there has been no study on the serum Mg2+ levels in patients with PSD. Our aim in this study was to explore the possible link between serum Mg2+ levels and the occurrence of depression at 3 months after stroke.

MATERIALS AND METHODS

Two hundred nine patients admitted to the stroke unit, the First Affiliated Hospital, Wenzhou Medical University, were prospectively included in the study during the period from October 2013 to September 2014. Patients from 18 to 80 years of age with an acute ischemia stroke were included. The exclusion criteria were: severe cognitive impairment, severe aphasia, patients with a history of psychiatric disorders, renal insufficiency, metabolic abnormalities, significant acute medical illness and significant acute neurological illness. Patients taking Mg2+ supplementation were also excluded. The control cases (N = 120) were recruited from a health survey in a community of similar age and gender distribution to the acute ischemia stroke patients. The control cases had no a history of psychiatric illness or neurological disorders, and their score on the 17-Hamilton Scale was less than seven. The study protocol was approved by the Medical Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University. Written informed consent was obtained from the participants or their nearest relatives. Baseline clinical characteristics in patients with and without post-stroke depression at 3-months. Results were expressed as percentages or as medians (IQR) and means (SD). SD: standard deviation; IQR: interquartile range; BMI: body mass index; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; Mg2+: Magnesium; PSD: post-stroke depression; p < 0.001 compared with non-PSD; p < 0.05 compared with non-PSD; p < 0.001 compared with controls; p < 0.05 compared with controls. Depression assessments were performed by a neurologist/psychiatrist who was blind to the laboratory result of the stroke patients at 3 months after stroke [10, 11]. Stroke survivors finished the 17-Hamilton Rating Scale for Depression (HAMD) at the 3-month follow-up [12]. Patients with a Hamilton Depression Scale score > 7 were given the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for diagnosis of PSD. The serum Mg2+ levels were evaluated using the Dimethyl aniline blue colorimetric method with a Beckman Coulter AU5800 automatic analyzer. The Mg2+ levels were categorized into three groups according to tertiles: ≤ 0.84 mmol/L, 0.85-0.90 mmol/L and ≥ 0.91 mmol/L. The influence of the Mg2+ levels on PSD was estimated by binary logistic regression analysis, after adjusting for potential confounding variables. Statistical significance was defined as p < 0.05.

RESULTS

In the study population, 33.0% were females, and the average age was 60.97 ± 10.39 years. The median (quartiles) NIHSS score at admission was 3 (1-4). The baseline characteristics of the two groups are described in Table 1. Fifty-nine patients (28.2%) showed depression at 3 months after admission. The results indicated that the median serum Mg2+ levels were significantly different among PSD patients, non-PSD patients and normal subjects (p<0.001). Indeed, the median serum Mg2+ levels were significantly lower in PSD patients than in non-PSD patients (p<0.001). Significant differences were observed between the PSD and non-PSD groups in the Mg2+ level tertiles of patients (p = 0.013) (Table 2).
Table 1

Baseline clinical characteristics in patients with and without post-stroke depression at 3-months.

Non-PSD (n = 150)PSD (n = 59)Control (n = 120)
Demographic characteristics
Age (years), mean ± SD60.41±10.6362.39 ± 9.6659.47 ± 9.35
Female (%)39(26.0)30 (50.8)b d39 (32.5)
BMI (kgm-2), mean ± SD24.00±3.1324.69 ± 3.32
Education (years), median (IQR)5(1-7)3 (0-7)
Vascular risk factors (%)
  Hypertension139(92.7)54 (91.5)
  Diabetes mellitus41(27.3)29 (49.2)b
  Hyperlipidaemia72(48.0)33 (55.9)
  Coronary heart disease4(2.7)4 (6.8)
  History of stroke15(10.0)8 (13.6)
  Current smoking57(38.3)15 (27.8)
  Alcohol consumption61(41.5)15 (27.8)
  Systolic blood pressure (mmHg), mean ± SD157.12±22.78160.63 ± 22.52
  Diastolic blood pressure(mmHg), mean ± SD86.90±13.3784.31 ± 12.17
Lesion location
  Frontal lobe33 (22.0)11 (18.6)
  Parietal lobe29 (19.3)13 (22.0)
  Temporal lobe17 (11.3)8 (13.6)
  Occipital lobe20 (13.3)7 (11.9)
  Basal ganglia62 (41.3)27 (45.8)
  Brainstem23 (15.3)11 (18.6)
  Cerebellum7 (4.7)4 (6.8)
  Other78 (52.0)30 (50.8)
Neuropsychological function
  NIHSS at admission, median (IQR)3 (1-4)3.5 (2-6)b
mRS at discharge, median (IQR)1 (1-2)2 (1-3)b
Mg2+ (mmolL-1), median (IQR)0.88 (0.84 - 0.94)d0.84 (0.77-0.87)ac0.96 (0.84 - 1.07)
Mg2+ (mmolL-1), mean ± SD0.89 ± 0.10d0.83 ± 0.09ac0.94 ± 0.13

Results were expressed as percentages or as medians (IQR) and means (SD). SD: standard deviation; IQR: interquartile range; BMI: body mass index; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; Mg2+: Magnesium; PSD: post-stroke depression;

p < 0.001 compared with non-PSD;

p < 0.05 compared with non-PSD;

p < 0.001 compared with controls;

p < 0.05 compared with controls.

Table 2

Magnesium levels tertiles of patients

Non-PSD (n=150)PSD (n=59)p
Mg2+ category, n (% of total population)0.013
  Low tertile (≤0.84mmol/L)45(30.0%)30(50.8%)0.005
  Intermediate tertile (0.85-0.89 mmol/L)59(39.3%)19(32.2)0.337
  High tertile (≥0.90mmol/L)46(30.7%)10(16.9%)0.044
Magnesium levels tertiles of patients In the multivariate Logistic regression analysis, with the intermediate tertile taken as reference, the low tertile of Mg2+ level (≤0.84 nmol/l) was independently associated with the development of PSD (OR 2.614, 95% CI 1.178-5.798, p=0.018) after adjusting for the above potential confounders, whereas the high tertile of Mg2+ levels (≥0.91 mmol/l) with an OR 0.579 (95%CI 0.225-1.494, p=0.259). Moreover, gender and mRs at discharge were significantly associated with the development of PSD in acute ischemia stroke patients (Table 3).
Table 3

Multivariate logistic model of the clinical determinants of PSD

VariablesOR (95% CI)p
Magnesium0.006
  Low tertile2.614 (1.178-5.798)0.018
  High tertile0.579 (0.225-1.494)0.259
sex3.447 (1.702-6.981)0.001
NIHSS on admission1.151 (0.969-1.369)0.110
mRS at discharge1.534 (1.033-2.278)0.34
DM1.495 (0.734-3.044)0.267

PSD: post-stroke depression; OR: odds ratio; CI: confidence interval; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; DM: Diabetes mellitus

Multivariate logistic model of the clinical determinants of PSD PSD: post-stroke depression; OR: odds ratio; CI: confidence interval; NIHSS: National Institutes of Health Stroke Scale; mRS: modified Rankin Scale; DM: Diabetes mellitus

DISCUSSION

To the best of our knowledge, this is the first study to investigate the relationship between the serum Mg2+ levels and the post-stroke depression. Our study demonstrated that low serum Mg2+ was associated with the development of depression at 3 months after stroke, indicating the possible involvement of the NMDA receptors in this activity. To our knowledge, neuronal Mg2+ levels are highly important in the regulation of NMDA receptor excitability. In Mg2+ deficiency, the NMDA receptors become hyperexcitable [13], which means that fewer NMDA channels will be blocked. In contract, when the Mg2+ levels in the central nervous system (CNS) are low, the γ-aminobutyric acid (GABA) receptors are less stimulated [14], whose function is also regulated by Mg2+, which in turn relieves the Mg2+ block of the NMDA receptor. The final mechanism contributing to the hyperexcitability of NMDA-receptor abundant neurons is the inhibition of glutamate release from the presynaptic neuron, which leads to depressive behavior. One study found that NMDA receptor blockade at rest triggers rapid behavioral antidepressant response [15]. Several studies have proposed that Mg2+ may relieve depression by blocking the NMDA receptor, whose dysfunction is a major causative factor in depression pathology [16]. As a result of the described mechanisms, the Mg2+ deficiency caused by NMDA receptor hyperexcitability may contribute to the occurrence of PSD. Several limitations of this study should be noted. First, the serum Mg2+ levels were assessed only once at admission. Second, the study was performed in only one clinical institute. In addition, patients who had more serious stroke died before the 3-month follow up were not included. Some patients who died and had depression might have been excluded.

Conclusion

The present study showed that, low serum Mg2+ levels at admission are associated with the development of depression at 3 months after stroke. Serum Mg2+ level alterations may play an important role in the presence of depression 3 months after stroke.
  16 in total

1.  Magnesium potentiation of the function of native and recombinant GABA(A) receptors.

Authors:  T Möykkynen; M Uusi-Oukari; J Heikkilä; D M Lovinger; H Lüddens; E R Korpi
Journal:  Neuroreport       Date:  2001-07-20       Impact factor: 1.837

2.  Intakes of magnesium, potassium, and calcium and the risk of stroke among men.

Authors:  Sally N Adebamowo; Donna Spiegelman; Alan J Flint; Walter C Willett; Kathryn M Rexrode
Journal:  Int J Stroke       Date:  2015-06-04       Impact factor: 5.266

3.  Dietary magnesium deficiency alters gut microbiota and leads to depressive-like behaviour.

Authors:  Gudrun Winther; Betina M Pyndt Jørgensen; Betina Elfving; Denis Sandris Nielsen; Pernille Kihl; Sten Lund; Dorte Bratbo Sørensen; Gregers Wegener
Journal:  Acta Neuropsychiatr       Date:  2015-02-18       Impact factor: 3.403

4.  Magnesium intake and incidence of stroke: meta-analysis of cohort studies.

Authors:  Z-L Nie; Z-M Wang; B Zhou; Z-P Tang; S-K Wang
Journal:  Nutr Metab Cardiovasc Dis       Date:  2012-07-11       Impact factor: 4.222

5.  Frequency of depression after stroke: a systematic review of observational studies.

Authors:  Maree L Hackett; Chaturangi Yapa; Varsha Parag; Craig S Anderson
Journal:  Stroke       Date:  2005-05-05       Impact factor: 7.914

6.  Intakes of potassium, magnesium, and calcium and risk of stroke.

Authors:  Ivonne Sluijs; Sebastien Czernichow; Joline W J Beulens; Jolanda M A Boer; Yvonne T van der Schouw; W Monique M Verschuren; Diederick E Grobbee
Journal:  Stroke       Date:  2014-02-11       Impact factor: 7.914

7.  Plasma levels of glutamate during stroke is associated with development of post-stroke depression.

Authors:  Sai-Yu Cheng; Yan-Dong Zhao; Jie Li; Xiao-Yan Chen; Ruo-Dan Wang; Jun-Wei Zeng
Journal:  Psychoneuroendocrinology       Date:  2014-05-17       Impact factor: 4.905

8.  Serum Brain-derived neurotrophic factor levels in post-stroke depression.

Authors:  Jie Li; Yan-Dong Zhao; Jun-Wei Zeng; Xiao-Yan Chen; Ruo-Dan Wang; Sai-Yu Cheng
Journal:  J Affect Disord       Date:  2014-07-18       Impact factor: 4.839

9.  Antidepressant-like activity of magnesium in the chronic mild stress model in rats: alterations in the NMDA receptor subunits.

Authors:  Bartłomiej Pochwat; Bernadeta Szewczyk; Magdalena Sowa-Kucma; Agata Siwek; Urszula Doboszewska; Wojciech Piekoszewski; Piotr Gruca; Mariusz Papp; Gabriel Nowak
Journal:  Int J Neuropsychopharmacol       Date:  2013-09-26       Impact factor: 5.176

Review 10.  Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis.

Authors:  Luis Ayerbe; Salma Ayis; Charles D A Wolfe; Anthony G Rudd
Journal:  Br J Psychiatry       Date:  2013-01       Impact factor: 9.319

View more
  6 in total

1.  Evaluation of betulinic acid effects on pain, memory, anxiety, catalepsy, and oxidative stress in animal model of Parkinson's disease.

Authors:  M Abrishamdar; Yaghoob Farbood; A Sarkaki; M Rashno; M Badavi
Journal:  Metab Brain Dis       Date:  2022-06-16       Impact factor: 3.584

2.  Blood biomarkers of post-stroke depression after minor stroke at three months in males and females.

Authors:  Zhou Zhu; Suiqiang Zhu; Xiuli Qiu; He Wang; Yan Lan; Jinfeng Miao; Chensheng Pan; Wenzhe Sun; Guo Li; Yanyan Wang; Xin Zhao
Journal:  BMC Psychiatry       Date:  2022-03-03       Impact factor: 3.630

Review 3.  Zinc, Magnesium, Selenium and Depression: A Review of the Evidence, Potential Mechanisms and Implications.

Authors:  Jessica Wang; Phoebe Um; Barbra A Dickerman; Jianghong Liu
Journal:  Nutrients       Date:  2018-05-09       Impact factor: 5.717

Review 4.  Why not Intravenous Thrombolysis in Patients with Recurrent Stroke within 3 Months?

Authors:  Chuanjie Wu; Di Wu; Jian Chen; Chuanhui Li; Xunming Ji
Journal:  Aging Dis       Date:  2018-04-01       Impact factor: 6.745

5.  Magnesium and mood disorders: systematic review and meta-analysis.

Authors:  Danny Phelan; Patricio Molero; Miguel A Martínez-González; Marc Molendijk
Journal:  BJPsych Open       Date:  2018-07

6.  Vitamin D deficiency mediates the relationship between dietary patterns and depression: a case-control study.

Authors:  Gity Sotoudeh; Firoozeh Raisi; Maryam Amini; Reza Majdzadeh; Mahdieh Hosseinzadeh; Fatemeh Khorram Rouz; Maryam Khosravi
Journal:  Ann Gen Psychiatry       Date:  2020-06-03       Impact factor: 3.455

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.